TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8461508

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (1 microgram/kg per min, low dose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (2 micrograms/kg per min, high dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 30
Study: 3954933

Group type: EXPERIMENTAL
Intervention: 500 mg of amoxycillin as a single i.v. infusion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 500 mg of ampicillin as a single i.v. infusion
Number of subjects: 24
Study: 30328302

Group type: EXPERIMENTAL
Intervention: Sodium Fluoride (NaF)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Er:YAG laser plus Sodium Fluoride (L+NaF)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Other treatments (CPP-ACPF, HA-NaF-X, L+CPP-ACPF, L+HA-NaF-X)
Number of subjects: 80
Study: 25524404

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (20,000 IU/week) for 6 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (6 months of observation)
Number of subjects: 25
Study: 25539330

Group type: EXPERIMENTAL
Intervention: AlloDerm
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: DermaMatrix
Number of subjects: 128
Study: 23123549

Group type: EXPERIMENTAL
Intervention: PlasmaKinetic enucleation
Number of subjects: 80

Group type: COMPARATOR
Intervention: bipolar transurethral resection
Number of subjects: 80
Study: 21470370

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Platelet-poor plasma (PPP)
Number of subjects: 24
Study: 18049096

Group type: EXPERIMENTAL
Intervention: 99mTc‐HYNIC‐rh‐annexin‐V scintigraphy (TAS)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Visual analysis of ATU
Number of subjects: 38
Study: 16616018

Group type: EXPERIMENTAL
Intervention: Pre-myocardial infarction angina pectoris (pre-MIAP)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Inferior AMI
Number of subjects: 110
Study: 14604742

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg BID
Number of subjects: 1677

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg BID (adjusted for noncompliance)
Number of subjects: 1677

Group type: EXPERIMENTAL
Intervention: Discontinuing fluvastatin without switching to another lipid‐lowering medication
Number of subjects: 1677

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1677
Study: 10685657

Group type: EXPERIMENTAL
Intervention: IL-2 therapy (9 million IU/m2/d for 4 days, then 1.6 million IU/m2/d for 10 days)
Number of subjects: 79

Group type: COMPARATOR
Intervention: No further therapy (control group)
Number of subjects: 79
Study: 9514403

Group type: EXPERIMENTAL
Intervention: High-dose multivitamin supplements containing 5 mg folic acid, 0.4 mg hydroxycobalamin, and 50 mg pyridoxine
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: 5 mg folic acid
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: 0.5 mg folic acid
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Cobalamin supplementation
Number of subjects: 316
Study: 7825393

Group type: EXPERIMENTAL
Intervention: 1.2% Sodium lauryl sulfate (SLS) dentifrice
Number of subjects: 10

Group type: COMPARATOR
Intervention: SLS-free dentifrice
Number of subjects: 10
Study: 3135934

Group type: EXPERIMENTAL
Intervention: Carboplatin in combination with cyclophosphamide, doxorubicin, and hexamethylmelamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin in combination with cyclophosphamide, doxorubicin, and hexamethylmelamine
Number of subjects: 0
Study: 29603705

Group type: EXPERIMENTAL
Intervention: Articaine buccal infiltration
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lidocaine inferior alveolar nerve block
Number of subjects: 40
Study: 28185997

Group type: EXPERIMENTAL
Intervention: Vilaprisan (2mg daily) for 12 or 24 weeks, or two 12-week treatment periods separated by a break to allow one menstruation to occur.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ulipristal acetate (5mg daily) for 12 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 12 weeks followed by active treatment for 12 weeks.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vilaprisan (2mg daily) in different regimens.
Number of subjects: 0
Study: 26248820

Group type: EXPERIMENTAL
Intervention: ASA only
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: ASA+Clo
Number of subjects: 1065

Group type: COMPARATOR
Intervention: No antiplatelet medication
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: ASA or ASA+Clo
Number of subjects: 1065
Study: 23431209

Group type: EXPERIMENTAL
Intervention: Region-specific spinal manipulation
Number of subjects: 148

Group type: COMPARATOR
Intervention: Non-region-specific spinal manipulation
Number of subjects: 148
Study: 20221953

Group type: EXPERIMENTAL
Intervention: Computerized aphasia treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phase 3 study of computerized aphasia treatment
Number of subjects: 0
Study: 18171452

Group type: EXPERIMENTAL
Intervention: Open-label conditioned placebo dose reduction (CPDR) treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control groups (not specified)
Number of subjects: 70
Study: 16996860

Group type: EXPERIMENTAL
Intervention: Low amount-moderate intensity aerobic exercise (energy equivalent of approximately 19.3 km/wk at 40%-55% peak VO2)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Low amount-high intensity aerobic exercise (energy equivalent of approximately 19.3 km/wk at 65%-80% peak VO2)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: High amount-high intensity aerobic exercise (energy equivalent of approximately 32.2 km/wk at 65%-80% peak VO2)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Inactivity (control group)
Number of subjects: 193
Study: 14644721

Group type: EXPERIMENTAL
Intervention: Anecortave acetate (15 mg)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 11011475

Group type: EXPERIMENTAL
Intervention: GP-based recruitment strategy
Number of subjects: 303

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 303
Study: 8839380

Group type: EXPERIMENTAL
Intervention: Tiger Balm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 0
Study: 1363923

Group type: EXPERIMENTAL
Intervention: Clotiazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etizolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 4005175

Group type: EXPERIMENTAL
Intervention: Young red cells (YRBC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Whole blood
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Filtered blood
Number of subjects: 48
Study: 31386583

Group type: EXPERIMENTAL
Intervention: Core-muscle-training program (8 weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (daily practice only)
Number of subjects: 17
Study: 29395114

Group type: EXPERIMENTAL
Intervention: GuttaCore
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cold Lateral Condensation (CLC)
Number of subjects: 24
Study: 26335402

Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg Q4W
Number of subjects: 1961

Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg Q4W
Number of subjects: 1961
Study: 24057871

Group type: EXPERIMENTAL
Intervention: Interactive e-health intervention
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Integrated clinical and occupational care management
Number of subjects: 215
Study: 22794222

Group type: EXPERIMENTAL
Intervention: Mechanical cycling (MC) with apical pressure filling techniques (lateral compaction)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Mechanical cycling (MC) with apical pressure filling techniques (Tagger's hybrid)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Mechanical cycling (MC) alone
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Filled groups (passive technique, lateral compaction, Tagger's hybrid)
Number of subjects: 70
Study: 20554457

Group type: EXPERIMENTAL
Intervention: Anterior temporal lobectomy combined with anterior corpus callosotomy (ATL + aCCT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Anterior temporal lobectomy (ATL)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Anterior corpus callosotomy (aCCT)
Number of subjects: 60
Study: 17140810

Group type: EXPERIMENTAL
Intervention: Intervention study of back supports and education
Number of subjects: 454
Study: 15608030

Group type: EXPERIMENTAL
Intervention: Intravaginal contraceptive releasing 120 microg/day of etonogestrel and 15 microg/day of ethinylestradiol (EE) (group A)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Oral contraceptive containing 20 microg di EE and 150 microg of desogestrel (group B)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 51
Study: 12200684

Group type: EXPERIMENTAL
Intervention: Reinforced courses of chemotherapy (standard 3+7 including high-dose daunorubicin, double induction, and timed-sequential therapy)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Reinforced courses of chemotherapy
Number of subjects: 159
Study: 10429606

Group type: EXPERIMENTAL
Intervention: Intramedullary bone-cement fixation with conventional plate and screw fixation
Number of subjects: 5
Study: 7572320

Group type: EXPERIMENTAL
Intervention: Oral dimethyl-APD (100-400 mg/day)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intravenous dimethyl-APD (4 mg/day)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Febrile response group
Number of subjects: 38
Study: 2142705

Group type: EXPERIMENTAL
Intervention: Early thrombolytic therapy (administered at 7 hours)
Number of subjects: 1638

Group type: EXPERIMENTAL
Intervention: Late thrombolytic therapy (administered at 11 hours)
Number of subjects: 1638

Group type: EXPERIMENTAL
Intervention: Late thrombolytic therapy (administered at 17 hours)
Number of subjects: 1638

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (timing not specified)
Number of subjects: 1638
Study: 508503

Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Temazepam 30 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg (Scherer formulation)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amylobarbitone 100 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30247159

Group type: EXPERIMENTAL
Intervention: Motor control training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 40
Study: 28928176

Group type: EXPERIMENTAL
Intervention: Higher CONUT scores
Number of subjects: 336

Group type: COMPARATOR
Intervention: Higher body mass index (24.25±3.05)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Higher haemoglobin (123.78±17.05)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Higher albumin levels
Number of subjects: 336

Group type: COMPARATOR
Intervention: Lower fasting blood glucose (6.90±2.48)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Higher GNRI score (99.42±6.55)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Lower CONUT (3.13±1.98)
Number of subjects: 336

Group type: COMPARATOR
Intervention: High-CONUT group
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Increasing CONUT risk
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: CONUT as a predictor
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: CONUT higher than 3.0
Number of subjects: 336
Study: 25591053

Group type: EXPERIMENTAL
Intervention: Therapeutic Tai Chi (10 different movements, 60 min, twice per week, for 6 weeks)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Therapeutic Tai Chi
Number of subjects: 22

Group type: COMPARATOR
Intervention: General physical therapy
Number of subjects: 22
Study: 22921688

Group type: EXPERIMENTAL
Intervention: Exercise + Pain Coping Skills Training (PCST)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Exercise + Non-Directive Counseling (NDC)
Number of subjects: 20
Study: 22397261

Group type: COMPARATOR
Intervention: Intravenous patient controlled analgesia (PCA) with morphine
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Femoral analgesia (FA) with 0.25% levobupivacain
Number of subjects: 71
Study: 19111318

Group type: EXPERIMENTAL
Intervention: Ferrous fumarate sprinkles
Number of subjects: 150

Group type: COMPARATOR
Intervention: Ferrous sulfate drops
Number of subjects: 150
Study: 16738295

Group type: EXPERIMENTAL
Intervention: Modified Macintosh laryngoscope blade
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Modified Miller laryngoscope blade
Number of subjects: 40

Group type: COMPARATOR
Intervention: Original Macintosh laryngoscope blade
Number of subjects: 40

Group type: COMPARATOR
Intervention: Original Miller laryngoscope blade
Number of subjects: 40
Study: 15625464

Group type: EXPERIMENTAL
Intervention: Arthroscopy-assisted open reduction and internal fixation (AORIF)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Open reduction and internal fixation without arthroscopy (ORIF)
Number of subjects: 72
Study: 11209968

Group type: EXPERIMENTAL
Intervention: E2 and P replacement
Number of subjects: 30
Study: 9373694

Group type: EXPERIMENTAL
Intervention: RSVP display
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scroll display
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cataract simulators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual acuity and contrast sensitivity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dynamic text displays
Number of subjects: 0
Study: 8405642

Group type: EXPERIMENTAL
Intervention: amoxycillin/clavulanate (AMX/CL) 2200 mg i.v. as a single dose
Number of subjects: 199

Group type: COMPARATOR
Intervention: cefuroxime plus metronidazole (CR/MN) 750/500 mg i.v. administered 3 times within 24 h
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: amoxycillin/clavulanate (AMX/CL)
Number of subjects: 199

Group type: COMPARATOR
Intervention: cefuroxime plus metronidazole (CR/MN)
Number of subjects: 199
Study: 3517256

Group type: EXPERIMENTAL
Intervention: Instruction group (received instruction about the unique physical and behavioral characteristics of premature infants)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Attention group (provided opportunity to discuss nonmedical concerns with the nurse researcher)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (received routine care and support from the intensive care nursery staff)
Number of subjects: 30
Study: 30829460

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - 1 year phoned physical activity advice individually adapted to physical assessment (twice a month during the first 6 months and then monthly)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Usual Care Group (UCG) - received current national recommendations in physical activity
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - breast cancer participants
Number of subjects: 301

Group type: COMPARATOR
Intervention: Usual Care Group (UCG) - breast cancer participants
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - female participants
Number of subjects: 301

Group type: COMPARATOR
Intervention: Usual Care Group (UCG) - female participants
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - normal nutritional status participants
Number of subjects: 301

Group type: COMPARATOR
Intervention: Usual Care Group (UCG) - normal nutritional status participants
Number of subjects: 301
Study: 29477692

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg or 2.0 mg monthly or pro re nata (PRN)
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment (monthly vs PRN)
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Baseline risk factors for month 24 MA presence
Number of subjects: 1095
Study: 27445542

Group type: EXPERIMENTAL
Intervention: High frequency chest wall oscillation (HFCWO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine pulmonary rehabilitation technique
Number of subjects: 30
Study: 24456373

Group type: EXPERIMENTAL
Intervention: CERA administered intravenously at weeks 0 and 2 (TWICE group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CERA administered intravenously at week 0 (ONCE group)
Number of subjects: 20
Study: 22156314

Group type: EXPERIMENTAL
Intervention: Landiolol (3 µg·kg(‐1)·min(‐1) for 24 h)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no landiolol administration)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Landiolol group
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 20167278

Group type: EXPERIMENTAL
Intervention: Defibrotide 25 mg/kg/day (arm A)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Defibrotide 40 mg/kg/day (arm B)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 149
Study: 18025879

Group type: EXPERIMENTAL
Intervention: PCV at week 0 and PPV at week 4 (n = 106)
Number of subjects: 212

Group type: COMPARATOR
Intervention: PPV alone at week 4 (n = 106)
Number of subjects: 212
Study: 16220212

Group type: EXPERIMENTAL
Intervention: Simplified time budget measure of activity levels
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Social Functioning Scale (SFS)
Number of subjects: 42
Study: 12113383

Group type: EXPERIMENTAL
Intervention: Individual dietary intervention for underweight patients (UW group)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Individual dietary intervention for overweight patients (OW group)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Individual dietary intervention for normal weight patients (NW group)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 87
Study: 10029805

Group type: EXPERIMENTAL
Intervention: Escherichia coli asparaginase
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Erwinia chrysanthemi asparaginase
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Pegaspargase
Number of subjects: 251

Group type: COMPARATOR
Intervention: In vitro nonresponders to asparaginase
Number of subjects: 251
Study: 7560366

Group type: EXPERIMENTAL
Intervention: Microcavity restorations
Number of subjects: 28

Group type: COMPARATOR
Intervention: Modified Black's Class II cavity restorations
Number of subjects: 28
Study: 2328959

Group type: EXPERIMENTAL
Intervention: Ethanol (10% solution in 5% dextrose in water)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (5% dextrose in water alone)
Number of subjects: 15
Study: 7016402

Group type: EXPERIMENTAL
Intervention: L-valine (600 mumol/min)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: L-isoleucine (150 mumol/min)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: L-leucine (300 mumol/min)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Mixture of branched-chain amino acids (70% L-leucine, 20% L-valine, 10% L-isoleucine; 270 mumol/min)
Number of subjects: 4
Study: 31837722

Group type: EXPERIMENTAL
Intervention: Coping Power Universal
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Control classes
Number of subjects: 1030
Study: 28393350

Group type: EXPERIMENTAL
Intervention: Parent-mediated social communication intervention (12 sessions delivered between 9 and 14 months of age)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Parent-mediated social communication intervention
Number of subjects: 54

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 54
Study: 26526317

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 91
Study: 23887247

Group type: EXPERIMENTAL
Intervention: Hypercapnia (PE'CO2 ≈ 50 mm Hg)
Number of subjects: 1215

Group type: COMPARATOR
Intervention: Normocapnia (PE'CO2 ≈ 35 mm Hg)
Number of subjects: 1215
Study: 20940355

Group type: EXPERIMENTAL
Intervention: Caffeic acid phenethyl esther
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Titanium tetrafluoride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Titanium tetrafluoride + caffeic acid phenethyl esther
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 19016732

Group type: EXPERIMENTAL
Intervention: Alemtuzumab consolidation therapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 21
Study: 18059399

Group type: EXPERIMENTAL
Intervention: Dietary intake of meat, total dietary iron, iron from meat, haem iron, and non-haem iron
Number of subjects: 34148
Study: 16267908

Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy and local-regional radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 11867243

Group type: EXPERIMENTAL
Intervention: CASC at 2 weeks (T(2W))
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: CASC at 3 months (T(3M))
Number of subjects: 110
Study: 10526275

Group type: EXPERIMENTAL
Intervention: Sequential therapy with cisplatin plus etoposide (n = 12)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Concurrent therapy with cisplatin plus etoposide (n = 18)
Number of subjects: 30

Group type: COMPARATOR
Intervention: (201)Tl retention
Number of subjects: 30
Study: 7476341

Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no weight loss intervention)
Number of subjects: 35
Study: 2301856

Group type: EXPERIMENTAL
Intervention: 0.3 ppm nitrogen dioxide (NO2)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Filtered air (control)
Number of subjects: 9
Study: 7034196

Group type: EXPERIMENTAL
Intervention: Diflunisal (DFS) 1g
Number of subjects: 15

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 4g
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diflunisal (DFS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 15
Study: 29660295

Group type: EXPERIMENTAL
Intervention: Nonexclusive breastfeeding
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Lack of support during the lactation period
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Difficulty breastfeeding
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Breastfeeding duration shorter than 12 months in a previous pregnancy
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Infants' birth weight less than 2,300 g
Number of subjects: 128